fetching data ...

OP0008 (2019)
SUSTAINED LOW DISEASE ACTIVITY AFTER WEIGHT LOSS TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND OBESITY; A 12-MONTHS FOLLOW-UP
Eva Klingberg1, Sofia Björkman2, Björn Eliasson3, Ingrid Larsson2, Annelie Bilberg4
1Sahlgrenska Academy at the University of Gothenburg, Sweden, Department of Rheumatology and Inflammation Research, Gothenburg, Sweden
2Sahlgrenska University Hospital, Gothenburg, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Sweden, Department of Gastroenterology and Hepatology, Gothenburg, Sweden
3Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Sweden, Department of Medicine, Gothenburg, Sweden
4Institute of Neuroscience and Physiology, Section of Health and Rehabilitation, Physiotherapy, Sahlgrenska Academy at the University of Gothenburg, Sweden, Gothenburg, Sweden

Background: Obesity is over-represented in patients with psoriatic arthritis (PsA) and associated with increased disease activity. We have previously shown in 41 patients with PsA (Caspar criteria) and obesity (body mass index BMI ≥33 kg/m 2 ) that weight loss treatment with Very Low Energy Liquid Diet (VLED), 640 kcal/day during 12-16 weeks, followed by a structured reintroduction of an energy restricted diet resulted in a median weight loss of 18.6% and concomitantly a significant improvement of the disease activity in joints, entheses and skin. At 6-months follow-up Psoriatic Arthritis Response Criteria (PsARC) was reached by 46.3% and American College of Rheumatology (ACR) 20, 50, 70 criteria for treatment response by 51.2%, 34.1% and 7.3% of the patients.


Objectives: To study the effects of the weight loss treatment on disease activity in longer term (12 months) in patients with PsA and obesity, when the patients are on a weight loss maintenance diet.


Methods: The patients were assessed with 66/68 joints count, Leeds enthesitis index, body surface area (BSA), questionnaires, CRP and BMI at the 12-months follow-up.


Results: Totally 39 PsA patients, median age 56 (IQR 49-63) years, 64% women were examined at the 12-month follow-up. The median weight reduction since baseline was 16.1 kg (IQR 10.5–22.8) or 16.0% (10.5–22.4). A majority of the disease activity parameters remained significantly improved (Table). At the 12-months follow-up PsARC was still fulfilled by 35.9% (n=14) and ACR 20, 50, 70 response criteria by 53.8% (n=21), 35.9% (n=14) and 15.5% (n=6) respectively.


Conclusion: Weight loss treatment with VLED in patients with PsA and obesity was associated with sustained weight reduction and lowered disease activity at 12-months follow-up.


Disclosure of Interests: Eva Klingberg Grant/research support from: Unrestricted grant from Roche, Consultant for: Novartis, Speakers bureau: Speakers fee from Lilly, Sofia Björkman: None declared, Björn Eliasson: None declared, Ingrid Larsson: None declared, Annelie Bilberg: None declared

DOI: 10.1136/annrheumdis-2019-eular.5551

Citation: Ann Rheum Dis, volume 78, supplement 2, year 2019, page A69
Session: Comorbidities in psoriatic arthritis (Scientific Abstracts)